These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. The effect of PPAR-alpha agonism on apolipoprotein metabolism in humans. Shah A; Rader DJ; Millar JS Atherosclerosis; 2010 May; 210(1):35-40. PubMed ID: 20005515 [TBL] [Abstract][Full Text] [Related]
6. The dual peroxisome proliferator-activated receptor alpha/gamma agonist tesaglitazar further improves the lipid profile in dyslipidemic subjects treated with atorvastatin. Tonstad S; Retterstøl K; Ose L; Ohman KP; Lindberg MB; Svensson M Metabolism; 2007 Sep; 56(9):1285-92. PubMed ID: 17697874 [TBL] [Abstract][Full Text] [Related]
7. Effect of tesaglitazar, a dual PPAR alpha/gamma agonist, on glucose and lipid abnormalities in patients with type 2 diabetes: a 12-week dose-ranging trial. Goldstein BJ; Rosenstock J; Anzalone D; Tou C; Ohman KP Curr Med Res Opin; 2006 Dec; 22(12):2575-90. PubMed ID: 17166340 [TBL] [Abstract][Full Text] [Related]
8. Effect of gemfibrozil on lipoprotein abnormalities in chronic renal insufficiency: a controlled study in human chronic renal disease. Samuelsson O; Attman PO; Knight-Gibson C; Kron B; Larsson R; Mulec H; Weiss L; Alaupovic P Nephron; 1997; 75(3):286-94. PubMed ID: 9069450 [TBL] [Abstract][Full Text] [Related]
9. The compositional abnormalities of lipoproteins in diabetic renal failure. Attman PO; Knight-Gibson C; Tavella M; Samuelsson O; Alaupovic P Nephrol Dial Transplant; 1998 Nov; 13(11):2833-41. PubMed ID: 9829487 [TBL] [Abstract][Full Text] [Related]
11. A novel compound that elevates high density lipoprotein and activates the peroxisome proliferator activated receptor. Bisgaier CL; Essenburg AD; Barnett BC; Auerbach BJ; Haubenwallner S; Leff T; White AD; Creger P; Pape ME; Rea TJ; Newton RS J Lipid Res; 1998 Jan; 39(1):17-30. PubMed ID: 9469582 [TBL] [Abstract][Full Text] [Related]
12. The effect of decreasing renal function on lipoprotein profiles. Attman PO; Samuelsson O; Alaupovic P Nephrol Dial Transplant; 2011 Aug; 26(8):2572-5. PubMed ID: 21220758 [TBL] [Abstract][Full Text] [Related]
13. Abnormal lipid and apolipoprotein composition of major lipoprotein density classes in patients with chronic renal failure. Attman PO; Alaupovic P; Tavella M; Knight-Gibson C Nephrol Dial Transplant; 1996 Jan; 11(1):63-9. PubMed ID: 8649654 [TBL] [Abstract][Full Text] [Related]
14. Enrichment of Triglyceride-Rich Lipoproteins with Apolipoprotein C-I Is Positively Associated with Their Delayed Plasma Clearance Independently of Other Transferable Apolipoproteins in Postmenopausal Overweight and Obese Women. Wassef H; Bissonnette S; Dufour R; Davignon J; Faraj M J Nutr; 2017 May; 147(5):754-762. PubMed ID: 28356429 [No Abstract] [Full Text] [Related]
16. Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention? Tenenbaum A; Fisman EZ Cardiovasc Diabetol; 2012 Nov; 11():140. PubMed ID: 23150952 [TBL] [Abstract][Full Text] [Related]
17. Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux. Guerin M; Egger P; Soudant C; Le Goff W; van Tol A; Dupuis R; Chapman MJ Atherosclerosis; 2002 Aug; 163(2):287-96. PubMed ID: 12052475 [TBL] [Abstract][Full Text] [Related]